ReviewAlimentary pharmacology & therapeutics2017
Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis.
Review in Alimentary pharmacology & therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 101 citations in OpenAlex.
- Role of Vitamin D in Systemic Sclerosis: A Systematic Literature Review.Journal of immunology research · 2021Pooled it
- Small intestinal bacterial overgrowth in systemic sclerosis: a review of the literature.Archives of dermatological research · 2019Pooled it
- Evolving prokinetic therapy: New targets and therapeutic opportunities in gastrointestinal motility disorders.World journal of gastrointestinal pharmacology and therapeutics · 2026Review
- Delayed gastric emptying identifies a high-risk clinical subgroup in patients with systemic sclerosis.Rheumatology (Oxford, England) · 2026Article
- Close association of kinesiophobia with physical performance in patients with systemic sclerosis.Rheumatology international · 2026Article
- Gastrointestinal involvement in very early and established systemic sclerosis: insights from the SPRING-SIR national Italian registry.Rheumatology (Oxford, England) · 2026Article
- Systemic Sclerosis-Related Intestinal Pseudo-Obstruction Mimicking Mechanical Small Bowel Obstruction.Cureus · 2026Article
- Case Report: Vascular abdominal pain in systemic sclerosis-chronic mesenteric ischemia from high-grade superior mesenteric artery stenosis with coexisting aortomesenteric narrowing.Frontiers in medicine · 2026Article
- Cellular Players in Gastrointestinal Involvement of Systemic Sclerosis: Insights into Pathogenesis.Cells · 2025Review
- Exploring endothelial dysfunction in major rheumatic diseases: current trends and future directions.Journal of molecular medicine (Berlin, Germany) · 2025Review
- Necrotising Pancreatitis in a Patient with Crest Syndrome: A Rare Autoimmune Gastrointestinal Complication.European journal of case reports in internal medicine · 2025Article
- Review
- Role of mechanoregulation in mast cell-mediated immune inflammation of the smooth muscle in the pathophysiology of esophageal motility disorders.American journal of physiology. Gastrointestinal and liver physiology · 2024Review
- Journey into the Esophageal Complications: Decoding Systemic Sclerosis with Cutting-Edge Endoscopy, Manometry, and Ambulatory pH-Study.International journal of general medicine · 2024Article
- Postoperative unexplained sigmoid stenosis in a patient with rectal cancer complicated with connective tissue disease: a case report and literature review.Frontiers in oncology · 2024Article
- The Collaborative National Quality and Efficacy Registry for Scleroderma: association of medication use on gastrointestinal tract symptoms in early disease and the importance of tobacco cessation.Clinical and experimental rheumatology · 2023Article
- Clinical phenotype in scleroderma patients based on autoantibodies.Rheumatology advances in practice · 2023Article
- Acute Spontaneous Colonic Perforation in a Case of Newly Confirmed Scleroderma: Case Report.Interactive journal of medical research · 2023Article
- Systemic sclerosis gastrointestinal dysmotility: risk factors, pathophysiology, diagnosis and management.Nature reviews. Rheumatology · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundGastrointestinal tract (GIT) involvement is a common cause of debilitating symptoms in patients with systemic sclerosis (SSc). There are no disease modifying therapies for this condition and the treatment remains symptomatic, largely owing to the lack of a clear understanding of its pathogenesis.
aimsTo investigate novel aspects of the pathogenesis of gastrointestinal involvement in SSc. To summarise existing knowledge regarding the cardinal clinical gastrointestinal manifestations of SSc and its pathogenesis, emphasising recent investigations that may be valuable in identifying potentially novel therapeutic targets.
methodsElectronic (PubMed/Medline) and manual Google search.
resultsThe GIT is the most common internal organ involved in SSc. Any part of the GIT from the mouth to the anus can be affected. There is substantial variability in clinical manifestations and disease course and symptoms are nonspecific and overlapping for a particular anatomical site. Gastrointestinal involvement can occur in the absence of cutaneous disease. Up to 8% of SSc patients develop severe GIT symptoms. This subset of patients display increased mortality with only 15% survival at 9 years. Dysmotiity of the GIT causes the majority of symptoms. Recent investigations have identified a novel mechanism in the pathogenesis of GIT dysmotility mediated by functional anti-muscarinic receptor autoantibodies.
conclusionsDespite extensive investigation, the pathogenesis of gastrointestinal involvement in systemic sclerosis remains elusive. Although treatment currently remains symptomatic, an improved understanding of novel pathogenic mechanisms may allow the development of potentially highly effective approaches including intravenous immunoglobulin and microRNA based therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.